| 发明名称 |
BIOMARKERS IN INFLAMMATORY BOWEL DISEASE |
| 摘要 |
The present invention provides a method of determining whether a patient with inflammatory bowel disease (IBD) and who has been treated with anti TNFα therapy is in immunological remission (IR), said method comprising determining the level of a cytokine selected from TNFα, IL-17 and IFN-γ in a G1 mucosal sample from said patient. Also provided are methods of prognosis and treatment using said method of determination, in particular discontinuing treatment if said patient is in IR and continuing treatment if said patient is not in IR. |
| 申请公布号 |
US2015323546(A1) |
申请公布日期 |
2015.11.12 |
| 申请号 |
US201314653750 |
申请日期 |
2013.12.23 |
| 申请人 |
UNIVERSITY OF TROMSØ |
发明人 |
Florholmen Jon;Olsen Trine;Rismo Renathe;Goll Rasmus;Cui Guanglin |
| 分类号 |
G01N33/68;G06F19/00;C12Q1/68 |
主分类号 |
G01N33/68 |
| 代理机构 |
|
代理人 |
|
| 主权项 |
1. A method of determining whether a patient with inflammatory bowel disease (IBD) and who has been treated with anti TNFα therapy is in immunological remission (IR), said method comprising determining the level of a cytokine selected from TNFα, IL-17 and IFN-γ in a GI mucosal sample from said patient. |
| 地址 |
Tromsø NO |
